(Q40240452)

18 September 2017

title

Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports (English)

1 reference

18 September 2017

Arif Khan

1

1 reference

18 September 2017

Kelly Schwartz

2

1 reference

18 September 2017

Nick Redding

3

1 reference

18 September 2017

Russell L Kolts

4

1 reference

18 September 2017

Walter A Brown

5

1 reference

18 September 2017

language of work or name

English

0 references

publication date

21 February 2007

1 reference

18 September 2017

published in

Neuropsychopharmacology

1 reference

18 September 2017

volume

32

1 reference

18 September 2017

issue

11

1 reference

18 September 2017

page(s)

2422-2430

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.npp.1301361

18 September 2017

exact match

0 references

cites work

Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

A comparison of paroxetine and placebo in depressed outpatients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

A Comparison of Paroxetine, Imipramine and Placebo in Depressed Out-patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Magnitude of placebo response and drug-placebo differences across psychiatric disorders.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Research design features and patient characteristics associated with the outcome of antidepressant clinical trials.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Placebo protects subjects from nonresponse: a paradox of power

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Dropout rates with olanzapine or risperidone: a multi-centre observational study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Sertraline treatment of panic disorder: results of a long-term study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301361

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1301361

1 reference

Dimensions Publication ID

18 September 2017

1013498570

0 references

1 reference